Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
A phase 2 trial of Evorpacept, Pembrolizumab in head and neck squamous cell carcinoma, run by ALX Oncology Inc., active and no longer recruiting.
Overview
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) is a phase 2 interventional study registered as NCT04675294 by ALX Oncology Inc., with 189 participants enrolled, started 2021-04-02 and due to reach its primary completion in 2025-03-03. Interventions recorded: evorpacept, pembrolizumab. Conditions listed: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialEvorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
Shares ALX Oncology, Evorpacept, Head and neck squamous cell carcinoma, Pembrolizumab.
- TrialA Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Shares ALX Oncology, Evorpacept.
- TrialASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Shares ALX Oncology, Evorpacept.